blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4111204

EP4111204 - DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  02.12.2022
Database last updated on 02.07.2024
FormerThe international publication has been made
Status updated on  03.09.2021
Formerunknown
Status updated on  05.03.2021
Most recent event   Tooltip05.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
4TEEN4 Pharmaceuticals GmbH
Neuendorfstrasse 15A
16761 Hennigsdorf / DE
[2023/01]
Inventor(s)01 / BERGMANN, Andreas
Am Rosenanger 78
13465 Berlin / DE
 [2023/01]
Representative(s)Kilger, Ute
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
[2023/01]
Application number, filing date21707707.226.02.2021
[2023/01]
WO2021EP54911
Priority number, dateEP2020015984827.02.2020         Original published format: EP 20159848
[2023/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021170838
Date:02.09.2021
Language:EN
[2021/35]
Type: A1 Application with search report 
No.:EP4111204
Date:04.01.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 02.09.2021 takes the place of the publication of the European patent application.
[2023/01]
Search report(s)International search report - published on:EP02.09.2021
ClassificationIPC:G01N33/68
[2023/01]
CPC:
G01N33/6893 (EP); C12Q1/37 (US); G01N33/573 (US);
G01N2800/26 (EP,US); G01N2800/52 (EP,US); G01N2800/56 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/01]
TitleGerman:DPP3 ZUR THERAPIEFÜHRUNG, ÜBERWACHUNG UND STRATIFIZIERUNG VON NT-ADM-ANTIKÖRPERN BEI PATIENTEN MIT SCHOCK[2023/01]
English:DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK[2023/01]
French:DPP3 POUR LE GUIDAGE, LA SURVEILLANCE ET LA STRATIFICATION THÉRAPEUTIQUE D'ANTICORPS NT-ADM CHEZ DES PATIENTS PRÉSENTANT UN CHOC[2023/01]
Entry into regional phase22.09.2022National basic fee paid 
22.09.2022Designation fee(s) paid 
22.09.2022Examination fee paid 
Examination procedure22.09.2022Examination requested  [2023/01]
22.09.2022Date on which the examining division has become responsible
17.04.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
12.01.2023Renewal fee patent year 03
04.01.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YD]WO2017182561  (SPHINGOTEC THERAPEUTICS GMBH [DE]) [YD] 1-28 * Abstract; example 1; claims 26-41; p. 1, first paragraph; example 5, Fig. 2B; Fig. 10 *;
 [Y]WO2019077082  (ADRENOMED AG [DE]) [Y] 1-28 * Abstract;pp. 8-10; claims; examples *;
 [YD]  - KOJI TAKAGI ET AL, "Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial", EUROPEAN JOURNAL OF HEART FAILURE, NL, (20190831), vol. 22, no. 2, doi:10.1002/ejhf.1600, ISSN 1388-9842, pages 279 - 286, XP055681198 [YD] 1-28 * Title; Abstract;p. 280, left hand column, paragraph 2, last sentence;p. 283, left hand column, paragraph 2;p. 285, left hand column, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/ejhf.1600
 [YD]  - BENJAMIN DENIAU ET AL, "Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics", EUROPEAN JOURNAL OF HEART FAILURE, NL, (20190831), vol. 22, no. 2, doi:10.1002/ejhf.1601, ISSN 1388-9842, pages 290 - 299, XP055681384 [YD] 1-28 * Title; Abstract;p. 291, left hand column, paragraph 1, last sentence;p. 298, left hand column, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/ejhf.1601
 [YD]  - REHFELD LINDA ET AL, "Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples", THE JOURNAL OF APPLIED LABORATORY MEDICINE: AN AACC PUBLICATION, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, US, (20190430), vol. 3, no. 6, doi:10.1373/JALM.2018.027995, ISSN 2475-7241, pages 943 - 953, XP009519664 [YD] 1-28 * Title; Abstract;p. 994, left hand column,paragraph 3 *

DOI:   http://dx.doi.org/10.1373/jalm.2018.027995
 [Y]  - MAGLIOCCA AURORA ET AL, "Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more", EUROPEAN JOURNAL OF HEART FAILURE, NL, (20191215), vol. 22, no. 2, doi:10.1002/ejhf.1649, ISSN 1388-9842, pages 300 - 302, XP055806857 [Y] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1002/ejhf.1649
 [IP]  - DENIAU BENJAMIN ET AL, "Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study", PLOS ONE, (20200827), vol. 15, no. 8, doi:10.1371/journal.pone.0238039, page e0238039, XP055806879 [IP] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0238039
 [IP]  - FRANÇOIS DÉPRET ET AL, "Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients", CRITICAL CARE, (20200422), vol. 24, no. 1, doi:10.1186/s13054-020-02888-5, XP055759383 [IP] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1186/s13054-020-02888-5
 [IP]  - BLET A ET AL, "Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study", CRITICAL CARE, UK, vol. 25, no. 1, doi:10.1186/s13054-021-03471-2, ISSN 1466-609X, (20210215), pages 1 - 10, URL: https://link.springer.com/content/pdf/10.1186/s13054-021-03471-2.pdf, XP055806855 [IP] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1186/s13054-021-03471-2
by applicantEP0353971
 WO9110741
 WO9117271
 WO9201047
 WO9220791
 WO9312227
 EP0622458
 US5585089
 US5807715
 EP1266025
 US2004023334
 WO2004097423
 WO2005040229
 WO2006027147
 EP1941867
 US2010028995
 WO2010060748
 EP2231860
 WO2011023685
 EP2314308
 WO2011073214
 WO2011154420
 WO2013072510
 WO2013072511
 WO2013072512
 WO2013072513
 WO2013072514
 WO2017182561
    - DOSTAL et al., JMol Cell Cardiol, (19970000), vol. 29, pages 2893 - 902
    - ROKS et al., Heart Vessels, (19970000), pages 119 - 24
    - CORREA et al., Crit Care, (20150000), vol. 19, page 98
    - REHFELD et al., JALM, (20190000), vol. 3, no. 6, pages 943 - 953
    - DEANIAU et al., Eur J Heart Fail., (20200000), vol. 22, no. 2, pages 279 - 286
    - KITAMURA et al., Biochem Biovhvs Res Comm, (19930000), vol. 192, no. 2, pages 553 - 560
    - WAN.!? et al., Peptides, (20010000), vol. 22, pages 1835 - 1840
    - HINSON et al., Endocrine Reviews, (20000000), vol. 21, no. 2, pages 138 - 16
    - KITAMURA et al., Biochem Biovhvs Res Commun, (19980000), vol. 244, no. 2, pages 551 - 555
    - PIO et al., The Journal of Biological Chemistry, (20010000), vol. 276, no. 15, pages 12292 - 12300
    - KUWASAKI et al., FEBS Lett, (19970000), vol. 414, no. 1, pages 105 - 110
    - KUWASAKI et al., Ann. Clin. Biochem., (19990000), vol. 36, pages 622 - 628
    - TSURUDA et al., Life Sci., (20010000), vol. 69, no. 2, pages 239 - 245
    - HIRATA et al., Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 4, pages 1449 - 1453
    - EHLENZ et al., Exp Clin Endocrinol Diabetes, (19970000), vol. 105, pages 156 - 162
    - VEDA et al., Am. J. Respir. Crit. Care Med., (19990000), vol. 160, pages 132 - 136
    - HIRAYAMA et al., JEndocrinol, (19990000), vol. 160, pages 297 - 303
    - YU et al., Heart, (20010000), vol. 86, pages 155 - 160
    - POVNER et al., Pharmacol Rev, (20020000), vol. 54, pages 233 - 246
    - LORENZ et al., Antimicrob Agents Chemother., (20110000), vol. 55, no. 1, pages 165 - 173
    - HULTSCHIS C et al., Curr Opin Chem Biol., (20060200), vol. 10, no. 1, pages 4 - 10
    - Kirk-Othmer, Encyclopedia of chemical technology, John Wiley & Sons, (19930000), vol. 15, pages 518 - 562
    - WEBER et al., JALM, (20170000), vol. 2, no. 2, pages 1 - 4
    - MARINO et al., Critical Care, (20140000), vol. 18, page R34
    - VINCENTDE BACKER, N. En l. J. Med., (20140000), vol. 370, no. 6, page 583
    - REVNOLDSHOCHMAN, Circulation, (20080000), vol. 117, page 686 69 7
    - HOCHMAN et al., J Am Coll Cardiol, (20000000), vol. 36, pages 1063 - 1070
    - GOLDBERG et al., Circulation, (20090000), vol. 119, pages 1211 - 1219
    - UDUPASHETTV, Indian JRespir Care, (20180000), vol. 7, pages 67 - 72
    - SINGER et al., JAMA, (20160000), vol. 315, no. 8, pages 801 - 10
    - WAGNER et al., Intensive Care Med Exp, (20130000), vol. 1, no. 1, page 21
    - GEVEN et al., Shock, (20180000), vol. 50, no. 2, pages 132 - 140
    - GEVEN et al., Intensive Care Med Exp, (20170000), vol. 5, no. 2, page 0427
    - LANZAVECCHIA et al., Eur. J. Immunol., (19870000), vol. 17, page 105
    - HUSTON et al., Proc. Natl. Acad. Sci. U.S.A., (19880000), vol. 85, pages 5879 - 5883
    - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
    - HUNKAPILLERHOOD, Nature, (19860000), vol. 321, pages 522 - 525
    - COULTERHARRIS, J. Immunol. Meth., (19830000), vol. 59, pages 199 - 203
    - ALMAGROFRANSSON, "Humanization of antibodies", Front Biosci., (20080101), vol. 13, pages 1619 - 33
    - LANE, R.D., J. Immunol. Meth., (19850000), vol. 81, pages 223 - 228
    - ZIEGLER et al., Horm. Metab. Res., (19960000), vol. 28, pages 11 - 15
    - MARX et al., Monoclonal Antibody Production, ATLA, (19970000), vol. 25, page 121
    - HUST et al., Journal of Biotechnology, (20110000), vol. 152, pages 159 - 170
    - SCHUTTE et al., PLoS One, (20090000), vol. 4, page e6625
    - LINDNER et al., Cancer Res., (20100000), vol. 70, pages 277 - 87
    - KAUFMANN et al., PNAS, (20100000), vol. 107, pages 14727 - 32
    - THOMAS et al., J. Exp. Med., (20090000), vol. 206, pages 1913 - 27
    - KONS et al., J. Cell Biol., (20090000), vol. 185, pages 1275 - 840
    - MARIANI et al., Mol. Immunol., (19910000), vol. 28, pages 489 - 498
    - BEALE, Exp Comp Immunol, (19870000), vol. 11, pages 287 - 96
    - ELLERSON et al., FEBS Letters, (19720000), vol. 24, no. 3, pages 318 - 22
    - KERBELELLIOT, Meth Enzvmol, (19830000), vol. 93, pages 113 - 147
    - KULKARNI et al., Cancer Immunol Immunotherapy, (19850000), vol. 19, pages 211 - 4
    - LAMOVI, Meth Enzymol, (19860000), vol. 121, pages 652 - 663
    - PARHAM et al., J Immunol Meth, (19820000), vol. 53, pages 133 - 73
    - RAVCHAUDHURI et al., Mol Immunol, (19850000), vol. 22, no. 9, pages 1009 - 19
    - ROUSSEAUX et al., Mol Immunol, (19800000), vol. 17, pages 469 - 82
    - ROUSSEAUX et al., J Immunol Meth, (19830000), vol. 64, pages 141 - 6
    - WILSON et al., J Immunol Meth, (19910000), vol. 138, pages 111 - 9
    - HARRISBAJORATH, Protein Sci., (19950000), vol. 4, pages 306 - 310
    - GEVEN et al., BMJ Open, (20190000), vol. 9, page e024475
 WO2005EP12844
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.